Identification of PRODH as a mitochondria and angiogenesis related biomarker for the lung adenocarcinoma

Le résumé fourni par la source

Abstract Background: The mitochondria and their associated genes were highly related to cellular metabolism. It plays a vital role in the therapy tumors. Angiogenesis is a critical process in the development and progression of tumors, including lung adenocarcinoma. Tumor growth and metastasis are dependent on angiogenesis. This study identified genes related to mitochondria and angiogenesis in lung adenocarcinoma. Based on the high and low expression of the genes in lung adenocarcinoma, we grouped them and conducted relevant bioinformatics analysis on differentially expressed genes. Results: We screened genes related to mitochondria and angiogenesis in the differential genes of lung adenocarcinoma, and identified PRODH as a gene of interest. The expression of PRODH was associated with the survival outcome of lung adenocarcinoma patients. Additionally, PRODH was also found to be associated with immune cell infiltration and tumor mutations. Conclusion: Mitochondrial metabolism and angiogenesis can have significant therapeutic benefits for lung adenocarcinoma (LUAD) patients. We identified a gene-PRODH which can promote tumor angiogenesis and contribute to tumor growth and metastasis. PRODH may be a prospective therapeutic target in LUAD as well as a possible diagnostic and prognostic biomarker associated with immune infiltration and Tumor Mutational Burden (TMB).

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.